Literature DB >> 2197339

A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli.

D A Weber1, C C Sanders, J S Bakken, J P Quinn.   

Abstract

A clinical Escherichia coli isolate (MG32) resistant to ceftazidime but susceptible to other third-generation cephalosporins was previously examined and found to harbor TEM-1 and exhibit alterations in outer membrane proteins. Reexamination of this isolate revealed the additional presence of a novel TEM-1 derivative, now designated TEM-12. Evaluation of ceftazidime and cefotaxime minimum inhibitory concentrations for isogenic derivatives demonstrated a major role for TEM-12 in the decreased susceptibility observed. This was selectively enhanced for ceftazidime resistance by the altered porins of E. coli MG32. TEM-12 appeared identical to TEM-101, an in vitro TEM derivative, in both isoelectric point (pI 5.25) and substrate profile. Hybridization and cloning of the TEM-12 determinant revealed that, unlike other TEM derivatives, TEM-12 is chromosomally encoded, not plasmid-encoded.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197339     DOI: 10.1093/infdis/162.2.460

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests.

Authors:  K S Thomson; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.

Authors:  L B Rice; L L Carias; A M Hujer; M Bonafede; R Hutton; C Hoyen; R A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Authors:  Sara K Olofsson; Patricia Geli; Dan I Andersson; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate.

Authors:  M C Poupart; C Chanal; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 6.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 7.  Is it important to identify extended-spectrum beta-lactamase-producing isolates?

Authors:  K Bush
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

8.  Updated sequence information for TEM beta-lactamase genes.

Authors:  S Goussard; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

9.  Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia.

Authors:  J K Rasheed; C Jay; B Metchock; F Berkowitz; L Weigel; J Crellin; C Steward; B Hill; A A Medeiros; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

10.  Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.

Authors:  P A Bradford; C E Cherubin; V Idemyor; B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.